Dosing & Uses
Dosage Forms & Strengths
400 mg PO qDay for 10 days
CrCl 30-49 mL/min: 200 mg PO qDay or 4.5 mg/kg qDay
CrCl 5-29 mL/min: 100 mg PO qDay or 2.25 mg/kg qDay
Supplement following hemodialysis
Other Indications & Uses
Mild to moderate respiratory tract infections (ie, acute exacerbation of chronic bronchitis) caused by susceptible bacteria
AOM caused by susceptible bacteria & pharyngitis/tonsillitis caused by Streptococcus pyogenes (group A beta-hemolytic streptococci)
Off-label: UTI caused by susceptible bacteria
Serious - Use Alternative
Significant - Monitor Closely
Increased BUN (4%)
Increased eosinophils (3%)
Decreased hemoglobin (2%)
Abdominal pain (1%)
Increased ALT (1%)
Increased bilirubin (1%)
Diabetics: oral suspension contains 1 g sucrose/tsp
Modify dosage in severe renal impairment; prolonged use may result in superinfection; caution in seizure disorder; may cause antibiotic associated colitis
Pregnancy & Lactation
Pregnancy Category: B
Lactation: excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Half-Life: 2.4 hr
Peak Plasma Time: 2-3 hr
Absorption: rapid; food decreases peak concentrations, delays Tmax, & lowers AUC
Vd: children: 0.5 L/kg; adults: 0.21 L/kg
Excretion: urine (56%); feces (39%)
Mechanism of Action
Third-generation cephalosporin that is bactericidal. Inhibits cell wall mucopeptide synthesis.
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs)
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.